Xbrane Eyes Positive Cash Flow In 2024 – But Out-Licensing Oncology Key
Swedish Firm In ‘Active Discussions With Potential Partners,’ Deal Possible In 2023
Xbrane has spelled out ambitious cash goals beginning next year, which hinge largely on it finding a partner for its pre-clinical oncology candidates, as it continues to shoulder heavy development and regulatory costs for its suite of biosimilars.
